Genomics


Figure 20 (right)


The Roche 454 GS FLX+ (left) and GS Junior Benchtop Systems (right)


Figure 21 (below) The Roche NimbleGen


SeqCap EZ Exome Library for amplicon assays


to achieve cost-efficient runs, and the speed and quality of data analysis. QIAGEN’s highly auto- mated workflow addresses these challenges by offering an ecosystem of automated products and services from primary sample to digital result (Figure 19).


Roche (www.454.com) is investing in three main areas in its NGS portfolio: 1) significant perform- ance and ease-of-use improvements to the 454 GS Junior Benchtop System and the GS FLX+ Systems; 2) an expanding menu of amplicon assays and SeqCap EZ target enrichment panels for transla- tional research applications; and 3) innovative technologies that will enable the next leap in per- formance, cost and scalability for the future of sequencing. The GS Junior System brings the power of NGS directly to the laboratory benchtop. Upcoming improvements will extend read length beyond 400bp to deliver more Sanger-like reads. New automation solutions will reduce hands-on time, drive lab efficiency and deliver powerful benchtop sequencing. The GS FLX+ System offers the unique combination of high throughput and long Sanger-like reads, with lengths up to 1,000bp and beyond. New developments will enable extra- long read amplicon sequencing on the GS FLX+ System for targeted gene sequencing and 16S metagenomics applications. Roche’s ready-to-run


38


amplicon assay menu is expanding to include new sequence-based assays for infectious disease (ie HIV drug resistance). These complement already available assays for leukaemia and human leuko- cyte antigen (HLA) typing research. In addition, Roche is investing in improvements to its portfolio of proven NimbleGen target enrichment products, including the SeqCap EZ Exome Library, SeqCap EZ Choice Library and SeqCap EZ Designs. Future sequencing technologies in development include semi-conductor-based sequencing system in collab- oration with DNA Electronics. This development builds on the current 454 pyrosequencing-based chemistry and will enable seamless evolution from optical detection to inexpensive, highly scalable electrochemical detection. Also in development is a single molecule nanopore-based sequencer in col- laboration with IBM and Arizona State University, which directly reads and decodes human DNA quickly and efficiently. This novel technology offers true single molecule sequencing by sequenc- ing molecules of DNA as they are threaded through a nanometer-sized pore in a solid-state sil- icon chip (Figures 20 and 21).


Discussion


NGS is an area renowned for its dynamism and the last two years have been no exception. Sequencers and their capabilities are in an almost constant


Drug Discovery World Spring 2013


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80